Viewpoint: Challenges and opportunities in tuberculosis research

Journal of Infectious Diseases

Volumn 205, Issue SUPPL. 2, 2012, Pages

  Kim, Peter S ^a   Makhene, Mamodikoe ^a   Sizemore, Christine ^a   Hafner, Richard ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; RIBOSOME RNA;

BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; COMORBIDITY; DIAGNOSTIC TEST; DRUG RESEARCH; DRUG RESISTANT TUBERCULOSIS; EPIDEMIOLOGICAL DATA; HEALTH CARE PLANNING; HEALTH CARE POLICY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFECTION PREVENTION; INFECTION RISK; MEDICAL RESEARCH; MIXED INFECTION; MOLECULAR DIAGNOSIS; MYCOBACTERIUM TUBERCULOSIS; NOTE; NUCLEIC ACID AMPLIFICATION; NUCLEIC ACID ANALYSIS; PATHOGEN LOAD; PRIORITY JOURNAL; SPUTUM ANALYSIS; TUBERCULOSIS; VACCINATION;

AGING; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; ORGANIC CHEMICALS; PANDEMICS; RESEARCH; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84860369390     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis190     Document Type: Note

References (18)

1. Global tuberculosis control 2011. WHO, 2011. www.who.int/tb/publications/ global-report/en/index.html. Accessed 23 January 2012.
2. Global Plan to Stop TB 2011-2015. WHO, STOP TB Partnership, 2010.
3. World Health Organization. Priority research questions for TB/HIV in HIV-prevalent and resource-limited settings. 2010. http://whqlibdoc. who.int/publications/2010/9789241500302-eng.pdf. Accessed 23 January 2012.
4. World Health Organization. Priorities in operational research to improve tuberculosis care and Control. WHO, 2011. http://www.google.com/url?q=http:// www.stoptb.org/assets/documents/resources/publications/technical/ StopTB%2520Guide.pdf&sa=U&ei=KxBIT9bgM8nDhAfklYSq Dg&ved= 0CBMQFjAA&usg=AFQjCNEgb-UiPfte6KzroxZ2upXUOvDq3A. Accessed 25 February 2012.
5. World Health Organization. An international roadmap for tuberculosis research. WHO, 2011; http://www.stoptb.org/news/stories/2011/ns11-072.asp. Accessed 25 February 2012.
6. Beresford B, Sadoff JC. Update on research and development pipeline: tuberculosis vaccines. Clin Infect Dis 2010; 50(Suppl 3):S178-83.
7. Kaufmann SH. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect Dis 2011; 11:633-40.
8. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365:11-20.
9. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010; 375:1920-37.
10. Nahid P, Saukkonen J, Mac Kenzie W, et al. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med 2011; 184:972-9.
11. Campbell PJ, Morlock GP, Sikes RD, et al. Molecular detection of mutations associated with first-and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55:2032-41.
12. Li L, Mahan CS, Palaci M, et al. Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy. J Clin Microbiol 2009; 48:46-51.
13. World Health Organization.Multidrug and extensively drug resistant TB: 2010 global report on surveillance and response.WHO, 2010. www.who. int/tb/publications/2010/978924599191/en/index.html. Accessed 25 February 2012.
14. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosisd2011 update.WHO, 2011. whqlibdoc.who.int/ publications/2011/9789241501583-eng.pdf. Accessed 15 January 2012.
15. Mitchison DA. The search for new sterilizing anti-tuberculosis drugs. Front Biosci 2004; 9:1059-72.
16. Mitchison DA. Basic mechanisms of chemotherapy. Chest 1979; 76: 771-81.
17. Mukamolova GV, Turapov O, Malkin J, Woltmann G, Barer MR. Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum. Am J Respir Crit Care Med 2010; 181:174-80.
18. Shi W, Zhang X, Jiang X, et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 2011; 333:1630-2.